SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq:
SGXP) will announce financial results for the first quarter of 2008 on
Tuesday May 13, 2008. The announcement will be followed by a live
conference call and webcast at 8:00 a.m. Pacific Time on that same day.
Mike Grey, President and Chief Executive Officer, Stephen Burley, Chief
Scientific Officer and Todd Myers, Chief Financial Officer, will host the
conference call to discuss financial results and business highlights.
A scientific backgrounder is available at http://www.sgxpharma.com/pipeline/posterspubs.php
Interested participants and investors may access the teleconference call by dialing 866-825-1709 (U.S./Canada) or 617-213-8060 (international), participant code 72662683. A telephonic replay will be available for seven days following the call. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international), participant code 83759897.
A live webcast will be available under the investor relations section of the Company's website at http://www.sgxpharma.com. Replays of the webcast will be available for 30 days following the event. Please connect to the Company's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About SGX Pharmaceuticals
SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been implicated in human cancers including JAK2, RON, ALK, RAS and IKK. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.
|SOURCE SGX Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved